Drug Resistance Updates
Volume 14, Issue 6 , Pages 280-296 , December 2011

Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies

  • Francesco Crea

      Affiliations

    • Division of Pharmacology, Department of Internal Medicine, University of Pisa, Pisa, Italy
    • These authors contributed equally to this work.
    • ,
  • Stefania Nobili

      Affiliations

    • Department of Preclinical and Clinical Pharmacology, University of Florence, Firenze, Italy
    • These authors contributed equally to this work.
    • ,
  • Elisa Paolicchi

      Affiliations

    • Division of Pharmacology, Department of Internal Medicine, University of Pisa, Pisa, Italy
    • ,
  • Gabriele Perrone

      Affiliations

    • Department of Preclinical and Clinical Pharmacology, University of Florence, Firenze, Italy
    • ,
  • Cristina Napoli

      Affiliations

    • Department of Preclinical and Clinical Pharmacology, University of Florence, Firenze, Italy
    • ,
  • Ida Landini

      Affiliations

    • Department of Preclinical and Clinical Pharmacology, University of Florence, Firenze, Italy
    • ,
  • Romano Danesi

      Affiliations

    • Division of Pharmacology, Department of Internal Medicine, University of Pisa, Pisa, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 050 992632.
    • ,
  • Enrico Mini

      Affiliations

    • Department of Preclinical and Clinical Pharmacology, University of Florence, Firenze, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 055 4271305; fax: +39 055 4271280.

Received 15 July 2011 ,Revised 9 August 2011 ,Accepted 13 August 2011.

References 

  1. Abele R, Clavel M, Dodion P, et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2’-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur. J. Cancer Clin. Oncol. 1987;23:1921–1924
  2. Adamsen BL, Kravik KL, Clausen OP, De Angelis PM. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int. J. Oncol. 2007;31:1491–1500
  3. Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene. 2006;25:4116–4121
  4. Aparicio A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother. Pharmacol. 2003;51:231–239
  5. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 2007;25:4603–4609
  6. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer. 2003;106:66–73
  7. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 1992;52:1855–1864
  8. Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br. J. Cancer. 2007;97:177–182
  9. Banerjee D, Gorlick R, Liefshitz A, et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res. 2000;60:2365–2367
  10. Banerjee D, Mayer-Kuckuk P, Capiaux G, et al. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta. 2002;1587:164–173
  11. Barbour KW, Berger SH, Berger FG. Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Mol. Pharmacol. 1990;37:515–518
  12. Baylin SB. Resistance, epigenetics and the cancer ecosystem. Nat. Med. 2011;17:288–289
  13. Belanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol. Biol. 2010;11:9–20
  14. Berger SH, Barbour KW, Berger FG. A naturally occorring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell line. Mol. Pharmacol. 1988;34:480–484
  15. Berger SH, Jenh CH, Johnson LF, Berger FG. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol. Pharmacol. 1985;28:461–467
  16. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 2009;27:1814–1821
  17. Bertino JR, Banerjee D. Thymidylate synthase as an oncogene?. Cancer Cell. 2004;5:301–302
  18. Birnie GD, Kroeger H, Heidelberger C. Studies of fluorinated pyrimidines, XVIII. The degradation of 5-fluoro-2’-deoxyuridine and related compounds by nucleoside phosphorylase. Biochemistry. 1963;2:566–572
  19. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–2087
  20. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006;5:769–784
  21. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res. 2008;14:6296–6301
  22. Broxterman HJ, Lankelma J, Pinedo HM. How to probe clinical tumour samples for P-glycoprotein and multidrug-resistance associated protein. Eur. J. Cancer. 1996;32A:1024–1033
  23. Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65:6305–6311
  24. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999;104:263–269
  25. Burger H, Zoumaro-Djayoon A, Boersma AW, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br. J. Pharmacol. 2010;159:898–908
  26. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist. Update. 2011;14:22–34
  27. Calascibetta A, Contino F, Feo S, et al. Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug response. J. Nucleic Acids. 2010;26:
  28. Camacho LH, Olson J, Tong WP, et al. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest. New Drugs. 2007;25:131–138
  29. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269:7–17
  30. Chang X, Monitto CL, Demokan S, et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 2010;70:2870–2879
  31. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response. Br. J. Cancer. 2008;98:1810–1819
  32. Chu E, Grem JL, Johnston PG, Allegra CJ. New concepts for the development and use of antifolates. Stem Cells. 1996;14:41–46
  33. Chu E, Koeller DM, Casey JL, et al. Autoregulation of hum an thymidylate synthase messenger RNA translation by thymidylate synthase. Proc. Natl. Acad. Sci. U.S.A. 1991;88:8977–8981
  34. Clark JL, Berger SH, Mittelman A, Berger FG. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treatm. Rep. 1987;71:261–265
  35. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistano to 5-fluorouracil. Biochem. Pharmacol. 1995;49:1419–1426
  36. Corsa P, Parisi S, Raguso A, et al. Temozolomide and radiotherapy as first-line treatment of high-grade gliomas. Tumori. 2006;92:299–305
  37. Crea F, Giovannetti E, Cortesi F, et al. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol. Cancer Ther. 2009;8:1964–1973
  38. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375:1030–1047
  39. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann. Intern. Med. 2011;154:37–49
  40. Danenberg PV, Langenbach RJ, Heidelberger C. Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotides. Biochemistry. 1974;13:926–933
  41. Davis AJ, Gelmon KA, Siu LL, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs. 2003;21:85–97
  42. de Bono JS, Kristeleit R, Tolcher A, et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin. Cancer Res. 2008;14:6663–6673
  43. Deng G, Chen A, Pong E, Kim YS. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene. 2001;20:7120–7127
  44. Deng G, Song GA, Pong E, Sleisenger M, Kim YS. Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. Cancer Res. 2004;64:2692–2698
  45. Deng G, Nguyen A, Tanaka H, et al. Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int. J. Cancer. 2006;118:2999–3005
  46. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell. Mol. Life Sci. 2002;59:1914–1927
  47. Di Gennaro E, Bruzzese F, Pepe S, et al. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol. Ther. 2009;8:782–791
  48. Dotor E, Cuatrecases M, Martínez-Iniesta M, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J. Clin. Oncol. 2006;24:1603–1611
  49. Dunn J, Baborie A, Alam F, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br. J. Cancer. 2009;101:124–131
  50. Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin. Reprod. Med. 2009;27:351–357
  51. Engelmann D, Pützer BM. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. Drug Resist. Update. 2010;13:119–131
  52. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin Ch. Histone deacetylase inhibitors and genomic instability. Cancer Lett. 2009;274:169–176
  53. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem. Pharmacol. 2003;66:225–237
  54. Fakih MG, Fetterly G, Egorin MJ, et al. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin. Cancer Res. 2010;16:3786–3794
  55. Fakih MG, Pendyala L, Fetterly G, et al. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin. Cancer Res. 2009;15:3189–3195
  56. Falcone A, Ricci S, Brunetti I, et al. Gruppo Oncologico Nord Ovest Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007;25:1670–1676
  57. Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int. J. Cancer. 2009;125:463–473
  58. Fernández-Contreras ME, Sánchez-Prudencio S, Sánchez-Hernández JJ, et al. Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int. J. Oncol. 2006;28:1303–1310
  59. Ferracin M, Gafà R, Miotto E, et al. The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. J. Pathol. 2008;214:594–602
  60. Flis S, Gnyszka A, Flis K, Spławiński J. MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. Eur. J. Pharmacol. 2010;627:26–32
  61. Flis S, Gnyszka A, Misiewicz-Krzemińska I, Spławiński J. Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205. Cancer Cell Int. 2009;9:1–10
  62. Flis S, Gnyszka A, Spławiński J. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem. Biophys. Res. Commun. 2009;387:336–341
  63. Fornaro L, Masi G, Loupakis F, Vasile E, Falcone A. Palliative treatment of unresectable metastatic colorectal cancer. Exp. Opin. Pharmacother. 2010;11:63–77
  64. Friedkin M, Roberts D. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J. Biol. Chem. 1954;207:245–256
  65. Fujita H, Kato J, Horii J, et al. Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells. Oncol. Rep. 2007;18:1129–1137
  66. Gagnon JF, Bernard O, Villeneuve L, Tetu B, Guillemette C. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin. Cancer Res. 2006;12:1850–1858
  67. Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 2001;7:2292–2300
  68. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2003;2:151–163
  69. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer. 2006;94:1087–1092
  70. Gore, L., Rothenberg, M.L., O’Bryant, C.L., et al., 2008. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 14, 4517–4525.
  71. Gosens MJ, Moerland E, Lemmens VP, et al. Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int. J. Cancer. 2008;123:1941–1949
  72. Hauswald S, Duque-Afonso J, Wagner MM, et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin. Cancer Res. 2009;15:3705–3715
  73. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–666
  74. Hollande F, Pannequin J, Joubert D. The long road to colorectal cancer therapy: searching for the right signals. Drug Resist. Update. 2010;13:44–56
  75. Holliday R. Epigenetics: a historical overview. Epigenetics. 2006;1:76–80
  76. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53
  77. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol. 2006;70:1390–1394
  78. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5’-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 1995;20:191–197
  79. Houghton JA, Maroda SJ, Phillips JO, Houghton PJ. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenograft of human colorectal adenocarcinomas in mice. Cancer Res. 1981;41:144–149
  80. Houghton JA, Torrance PM, Radparvar S, Williams LG, Houghton PJ. Binding of 5-fluorodeoxyuridylate to thymidylate synthase in human colon adenocarcinoma xenografts. Eur. J. Cancer Clin. Oncol. 1986;22:505–510
  81. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol. Pharmacol. 2010;77:887–894
  82. Hsu CH, Liou JY, Dutschman GE, Cheng YC. Phosphorylation of cytidine, deoxycytidine, and their analog monophosphates by human UMP/CMP kinase is differentially regulated by ATP and magnesium. Mol. Pharmacol. 2005;67:806–814
  83. Humeniuk R, Menon LG, Mishra PJ, et al. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol. Cancer Ther. 2009;8:1037–1044
  84. Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Mol. Cancer Ther. 2009;8:1045–1054
  85. Huo, H., Magro, P.G., Pietsch, E.C., Patel, B.B., Scotto, K.W., 2010. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 70, 8726–8735.
  86. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 2009;27:2604–2614
  87. Iltzsch MH, el Kouni MH, Cha S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry. 1985;24:6799–6807
  88. Issa JP. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat. Clin. Pract. Oncol. 2005;2(Suppl. 1):S24–S29
  89. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 1998;101:847–854
  90. Jacinto FV, Ballestar E, Ropero S, Esteller M. Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res. 2007;67:11481–11486
  91. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–130
  92. Jemal A, Bray F, Center MM, Ferlay J, Ward EME, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61:69–90
  93. Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol. 1994;12:2640–2647
  94. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20:85–93
  95. Jover R, Nguyen TP, Pérez-Carbonell L, et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology. 2011;140:1174–1181
  96. Kaina B, Ochs K, Grosch S, et al. BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis. Prog. Nucleic Acid Res. Mol. Biol. 2001;68:41–54
  97. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57:808–811
  98. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, Altman S. Role in translation of a triple tandemly repeated sequence in the 5’-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res. 1987;15:1259–1270
  99. Kawakami K, Salonga D, Park JM, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 2001;7:4096–4101
  100. Kelly WK, DeBono J, Blumenschein G, et al. Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2009;28:3531;(abstract)
  101. Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005;23:3031–3923
  102. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 2010;28:1069–1078
  103. Kidani Y, Inagaki K, Iigo M, Hoshi A, Kuretani K. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J. Med. Chem. 1978;21:1315–1318
  104. Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL. Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin. Cancer Res. 2005;11:2612–2619
  105. Kim JC, Shin ES, Kim CW, et al. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. Anticancer Res. 2009;29:3027–3034
  106. Kohne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist. 2009;14:478–488
  107. Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. Eur. J. Cancer. 2009;45:1935–1949
  108. Koopman M, Venderbosch S, van Tinteren H, et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomized CAIRO study. Eur. J. Cancer. 2009;45:1999–2006
  109. Kosuri KV, Wu X, Wang L, Villalona-Calero MA, Otterson GA. An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem. Biophys. Res. Commun. 2010;391:1465–1470
  110. Kuhn JG. Pharmacology of irinotecan. Oncology (Williston Park). 1998;12:39–42
  111. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treatm. Rev. 2005;31:90–105
  112. Landis DM, Loeb LA. Random sequence mutagenesis and resistance to 5-fluorouridine in human thymidylate synthases. J. Biol. Chem. 1998;273:25809–25817
  113. Laurent A, Nicco C, Chéreau C, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65:948–956
  114. Lee JH, Park JH, Jung Y, et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol. Cancer Ther. 2006;5:3085–3095
  115. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br. J. Cancer. 1994;69:409–416
  116. Liang JT, Chang KJ, Chen JC, et al. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology. 1999;57:149–156
  117. Lin J, Gilbert J, Rudek MA, et al. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin. Cancer Res. 2009;15:6241–6249
  118. Lincz LF, Scorgie FE, Garg MB, Ackland SP. Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele. Int. J. Cancer. 2007;120:1930–1934
  119. Lockshin A, Danenberg PV. Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem. Pharmacol. 1981;30:247–257
  120. Lomen PL, Baker LH, Neil GL, Samson MK. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days. Cancer Chemother. Rep. 1975;59:1123–1126
  121. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim. Biophys. Acta. 2006;1766:184–196
  122. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer. 2003;3:330–338
  123. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432:307–315
  124. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst. 2005;97:1498–1506
  125. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5’ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003;63:2898–2904
  126. Martinez-Balibrea E, Martínez-Cardús A, Musulén E, et al. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int. J. Cancer. 2009;124:2905–2910
  127. Malet-Martino M, Jolimaitre P, Martino R. The prodrugs of 5-fluorouracil. Curr. Med. Chem. Anticancer Agents. 2002;2:267–310
  128. Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics. 2010;11:1003–1010
  129. Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed. Pharmacother. 1989;43:237–250
  130. Mathews LA, Crea F, Farrar WL. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation. 2009;78:1–17
  131. Mellai M, Caldera V, Annovazzi L, et al. MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genom. Proteom. 2009;6:219–227
  132. McClard RW, Black MJ, Livingstone LR, Jones ME. Isolation and initial characterization of the single polypeptide that synthesizes uridine 5’-monophosphate from orotate in Ehrlich ascites carcinoma. Purification by tandem affinity chromatography of uridine-5’-monophosphate synthase. Biochemistry. 1980;19:4699–4706
  133. McDermott, U., Longley, D.B., Galligan, L., et al., 2005. Effect of p53 status and STAT1 on chemotherapy induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 65, 8951–8960.
  134. Metzger R, Danenberg K, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res. 1998;4:2371–2376
  135. Mini E, Trave F, Rustum YM, Bertino JR. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol. Ther. 1990;47:1–19
  136. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: a review. Crit. Rev. Oncol. Hematol. 2000;35:75–93
  137. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 1972;56:649–652
  138. Mulkins MA, Heidelberger C. Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res. 1982;42:965–973
  139. Münster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol. 2007;25:1979–1985
  140. Munster PN, Marchion D, Thomas S, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br. J. Cancer. 2009;101:1044–1050
  141. Munster PN, Petrou P, Ryan CJ, et al. A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies. Proc. Am. Soc. Clin. Oncol. 2010;29:e13140;(abstract)
  142. Na YS, Kim SM, Jung KA, et al. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts. Oncol. Rep. 2010;24:1509–1514
  143. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidlinesTM) - Colon cancer. Version 3.2011. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
  144. Nelson MA, Shetty S, Kulakodlu M, Harley C, Seal B. A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer. J. Med. Econ. 2011;14:179–186
  145. Newman EM, Longmate JA, Lenz HJ, et al. Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2’-deoxycytidine: a California Cancer Consortium study. Proc. Am. Soc. Clin. Oncol. 2002;21:431;(abstract)
  146. Nief N, Le Morvan V, Robert J. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. Eur. J. Cancer. 2007;43:955–962
  147. Nobili S, Napoli C, Landini I, et al. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Int. J. Cancer. 2011;128:1935–1945
  148. Noguchi T, Tanimoto K, Shimokuni T, et al. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin. Cancer Res. 2004;10:7100–7107
  149. Northfelt DW, Bonnem E, Fagerberg J, Von Hoff D, Grem J. Belinostat (Bel) down-regulates thymidylate synthase (TS) in tumor tissue: A dose-escalation study of belinostat alone and in combination with 5-fluorouracil (FU). Gastrointest. Cancer Symp. Am. Soc. Clin. Oncol. 2009;333:(abstract)
  150. Ocker M, Alajati A, Ganslmayer M, et al. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J. Cancer Res. Clin. Oncol. 2005;131:385–394
  151. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J. Mol. Diagn. 2008;10:13–27
  152. Ohtsuka T, Liu XF, Koga Y, et al. Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer. Oncogene. 2006;25:1807–1811
  153. Oki Y, Aoki E, Issa JP. Decitabine—bedside to bench. Crit. Rev. Oncol. Hematol. 2007;61:140–152
  154. Pasti C, Gallois-Montbrun S, Munier-Lehmann H, et al. Reaction of human UMP-CMP kinase with natural and analog substrates. Eur. J. Biochem. 2003;270:1784–1790
  155. Patnaik A, Rowinsky EK, Villalona MA, et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 2002;8:2142–2148
  156. Patterson AV, Zhang H, Moghaddam A, et al. Increased sensitivity to the prodrug 5’-deoxy-5-fluorouridine and modulation of 5-fluoro-2’-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer. 1995;72:669–675
  157. Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim. Biophys. Acta. 2002;1587:194–205
  158. Piunti A, Pasini D. Epigenetic factors in cancer development: polycomb group proteins. Future Oncol. 2011;7:57–75
  159. Pizzorno G, Handschumacher RE. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem. Pharmacol. 1995;49:559–565
  160. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039–6044
  161. Plummer R, Vidal L, Griffin M, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin. Cancer Res. 2009;15:3177–3183
  162. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol. 2004;22:529–536
  163. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 2009;15:3958–3969
  164. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1:65–70
  165. Qiao L, Wong BCY. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist. Update. 2009;12:55–64
  166. Quagliana JM, O’Bryan RM, Baker L, et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treatm. Rep. 1977;61:51–54
  167. Radparvar S, Houghton PJ, Houghton JA. Effect of 5,10-methylentetrahydrofolate on the binding of 5-fluoro-2’-deoxyuridylate to thymidilate synthase purified from a human colon adenocarcinoma xenografts. Biochem. Pharmacol. 1989;38:335–342
  168. Rahman L, Voeller D, Rahman M, et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell. 2004;5:341–351
  169. Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed. Chromatogr. 2010;24:104–123
  170. Ramirez J, Ratain MJ, Innocenti F. Uridine 5’-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010;6:563–585
  171. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 2002;1:227–235
  172. Redmond KM, Wilson TR, Johnston PG, Longley DB. Resistance mechanisms to cancer chemotherapy. Front Biosci. 2008;13:5138–5154
  173. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 2001;98:10833–10838
  174. Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol. 2005;53:13–23
  175. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 2000;6:1322–1327
  176. Sanguedolce R, Alessandro R, De Leo G, et al. Failure of detection of the tyrosine to histidine substitution at the residue 33 of thymidylate synthase in human colorectal cancer. A preliminary study. Anticancer Res. 2000;20:4347–4350
  177. Santelli G, Valeriote F. In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides. J. Natl. Cancer Inst. 1980;64:69–72
  178. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry. 1974;13:471–481
  179. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker.for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010;28:3219–3226
  180. Sato K, Kitajima Y, Miyoshi A, Koga Y, Miyazaki K. Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. Int. J. Oncol. 2006;29:429–435
  181. Sawan C, Herceg Z. Histone modifications and cancer. Adv. Genet. 2010;70:57–85
  182. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl. Acad. Sci. U.S.A. 2006;103:1412–1417
  183. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res. 2006;12:5777–5785
  184. Schwartsmann G, Schunemann H, Gorini CN, et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest. New Drugs. 2000;18:83–91
  185. Schwartz EL, Baptiste N, Wadler S, Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J. Biol. Chem. 1995;270:19073–19077
  186. Shen L, Catalano PJ, Benson AB, O’Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res. 2007;13:6093–6098
  187. Shnider BI, Baig M, Colsky J. A phase I study of 5-azacytidine (NSC-102816). J. Clin. Pharmacol. 1976;16:205–212
  188. Siu LL, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J. Clin. Oncol. 2008;26:1940–1947
  189. Soong R, Shah N, Salto-Tellez M, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann. Oncol. 2008;19:915–919
  190. Soussi T, Ishioka C, Claustres M, Bèroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer. 2006;6:83–90
  191. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Update. 2003;6:71–84
  192. Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 2008;14:804–810
  193. Stewart DJ, Donehower RC, Eisenhauer EA, et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann. Oncol. 2003;14:766–774
  194. Sugita H, Iida S, Inokuchi M, et al. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol. Rep. 2011;25:513–518
  195. Sung MW, Waxman S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res. 2007;27:995–1001
  196. Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 2005;115:1492–1502
  197. Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist. Update. 2008;11:231–246
  198. Tempestini A, Caciagli B, Morganti M, et al. Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules. Oncol. Res. 2006;16:143–156
  199. Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 2010;28:866–871
  200. Tokunaga Y, Sasaki H, Saito T. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery. 2007;141:346–353
  201. Tong Y, Liu-Chen X, Ercikan-Abali EA, et al. Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. J. Biol. Chem. 1998;273:11611–11618
  202. Tumber A, Collins LS, Petersen KD, et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother. Pharmacol. 2007;60:275–283
  203. Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. 2000;9:1381–1385
  204. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011;29:2011–2019
  205. Van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol. 2011;29:1382–1391
  206. Van Groeningen CJ, Leyva A, O’Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2’-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986;46:4831–4836
  207. Van Rompay AR, Johansson M, Karlsson A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol. Ther. 2000;87:189–198
  208. Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. New Drugs. 2008;26:483–488
  209. Vignoli M, Nobili S, Napoli C, et al. Thymidylate synthase expression and genotype have no major impact on theclinical outcome of colorectal cancer patients treated with 5-fluorouracil. Pharmacol. Res. 2011;64:242–248
  210. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 2005;11:6212–6217
  211. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat. Rev. Clin. Oncol. 2010;7:153–162
  212. Vilar E, Scaltriti M, Balmana J, et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br. J. Cancer. 2008;99:1607–1612
  213. Wang CG, Ye YJ, Yuan J, et al. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J. Gastroenterol. 2010;16:2421–2427
  214. Wang TL, Diaz LA, Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc. Natl. Acad. Sci. U.S.A. 2004;101:3089–3094
  215. Watson RG, Muhale F, Thorne LB, et al. Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. Eur. J. Cancer. 2010;46:3358–3364
  216. Weber W. Cancer epigenetics. Prog. Mol. Biol. Transl. Sci. 2010;95:299–349
  217. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006;38:787–793
  218. Weiss AJ, Metter GE, Nealon TF, et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat. Rep. 1977;61:55–58
  219. Westra JL, Hollema H, Schaapveld M, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann. Oncol. 2005;16:1646–1653
  220. Whitehead RP, Rankin C, Hoff PM, et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest. New Drugs. 2009;27:469–475
  221. Wilson PM, El-Khoueiry A, Iqbal S, et al. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother. Pharmacol. 2010;65:979–988
  222. Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets. 2009;9:307–319
  223. Wu JT, Archer SY, Hinnebusch B, Meng S, Hodin RA. Transient vs. prolonged histone hyperacetylation: effects on colon cancer cell growth, differentiation, and apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2001;280:G482–G490
  224. Yanagisawa Y, Maruta F, Iinuma N, et al. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. Scand. J. Gastroenterol. 2007;42:477–484
  225. Yin MB, Zakrzewski SF, Hakala MT. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol. Pharmacol. 1983;23:190–197
  226. Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab. Dispos. 2008;36:2299–2306
  227. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 2006;319:879–886
  228. Yoo BK, Gredler R, Vozhilla N, et al. Identification of genes conferring resistance to 5-fluorouracil. Proc. Natl. Acad. Sci. U.S.A. 2009;106:12938–12943
  229. Yu J, Miller R, Zhang W, et al. Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics. 2008;9:1459–1466
  230. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003;100:1931–1936
  231. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 2000;290:989–992
  232. Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006;66:8847–8857

PII: S1368-7646(11)00060-4

doi: 10.1016/j.drup.2011.08.001

Drug Resistance Updates
Volume 14, Issue 6 , Pages 280-296 , December 2011

Article Tools

* Image Usage & Resolution